vs
Clearfield, Inc.（CLFD）与RHYTHM PHARMACEUTICALS, INC.（RYTM）财务数据对比。点击上方公司名可切换其他公司
RHYTHM PHARMACEUTICALS, INC.的季度营收约是Clearfield, Inc.的1.7倍（$57.3M vs $34.3M），Clearfield, Inc.净利率更高（-1.8% vs -83.0%，领先81.2%），RHYTHM PHARMACEUTICALS, INC.同比增速更快（36.9% vs -3.2%），过去两年RHYTHM PHARMACEUTICALS, INC.的营收复合增速更高（48.5% vs -3.5%）
Clearfield, Inc.总部位于美国明尼苏达州明尼阿波利斯市，是一家专注于光纤产品研发生产的企业，其产品主要应用于光纤通信网络建设领域，为通信基础设施部署提供相关硬件支撑。
Rhythm Pharmaceuticals是一家专注于罕见病领域的生物制药企业，主要开发和商业化针对罕见遗传性肥胖症的靶向疗法，覆盖POMC缺陷、LEPR缺陷、巴德-毕德氏综合征等适应症，服务北美、欧洲地区缺少有效治疗方案的患者群体。
CLFD vs RYTM — 直观对比
营收规模更大
RYTM
是对方的1.7倍
$34.3M
营收增速更快
RYTM
高出40.1%
-3.2%
净利率更高
CLFD
高出81.2%
-83.0%
两年增速更快
RYTM
近两年复合增速
-3.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.3M | $57.3M |
| 净利润 | $-614.0K | $-47.5M |
| 毛利率 | 33.2% | 91.6% |
| 营业利润率 | -5.3% | -82.2% |
| 净利率 | -1.8% | -83.0% |
| 营收同比 | -3.2% | 36.9% |
| 净利润同比 | 67.8% | -9.6% |
| 每股收益（稀释后） | $-0.04 | $-0.73 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLFDRYTM
| Q4 25 | $34.3M | $57.3M | ||
| Q3 25 | $23.4M | $51.3M | ||
| Q2 25 | $49.9M | $48.5M | ||
| Q1 25 | $47.2M | $32.7M | ||
| Q4 24 | $29.7M | $41.8M | ||
| Q3 24 | $5.6M | $33.3M | ||
| Q2 24 | $48.8M | $29.1M | ||
| Q1 24 | $36.9M | $26.0M |
净利润CLFDRYTM
| Q4 25 | $-614.0K | $-47.5M | ||
| Q3 25 | $-9.1M | $-52.9M | ||
| Q2 25 | $1.6M | $-46.6M | ||
| Q1 25 | $1.3M | $-49.5M | ||
| Q4 24 | $-1.9M | $-43.3M | ||
| Q3 24 | — | $-43.6M | ||
| Q2 24 | $-447.0K | $-32.3M | ||
| Q1 24 | $-5.9M | $-141.4M |
毛利率CLFDRYTM
| Q4 25 | 33.2% | 91.6% | ||
| Q3 25 | 53.2% | 89.3% | ||
| Q2 25 | 30.5% | 88.6% | ||
| Q1 25 | 30.1% | 88.8% | ||
| Q4 24 | 29.2% | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | 21.9% | 89.9% | ||
| Q1 24 | 7.7% | 89.2% |
营业利润率CLFDRYTM
| Q4 25 | -5.3% | -82.2% | ||
| Q3 25 | 10.3% | -102.6% | ||
| Q2 25 | 3.0% | -93.4% | ||
| Q1 25 | 0.6% | -143.7% | ||
| Q4 24 | -6.9% | -98.6% | ||
| Q3 24 | — | -132.0% | ||
| Q2 24 | -4.7% | -139.2% | ||
| Q1 24 | -26.4% | -538.7% |
净利率CLFDRYTM
| Q4 25 | -1.8% | -83.0% | ||
| Q3 25 | -38.8% | -103.1% | ||
| Q2 25 | 3.2% | -96.1% | ||
| Q1 25 | 2.8% | -151.4% | ||
| Q4 24 | -6.4% | -103.6% | ||
| Q3 24 | — | -131.2% | ||
| Q2 24 | -0.9% | -110.9% | ||
| Q1 24 | -16.0% | -544.4% |
每股收益（稀释后）CLFDRYTM
| Q4 25 | $-0.04 | $-0.73 | ||
| Q3 25 | $-0.65 | $-0.82 | ||
| Q2 25 | $0.11 | $-0.75 | ||
| Q1 25 | $0.09 | $-0.81 | ||
| Q4 24 | $-0.13 | $-0.71 | ||
| Q3 24 | — | $-0.73 | ||
| Q2 24 | $-0.04 | $-0.55 | ||
| Q1 24 | $-0.40 | $-2.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $96.4M | $388.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $249.7M | $139.1M |
| 总资产 | $268.1M | $480.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLFDRYTM
| Q4 25 | $96.4M | $388.9M | ||
| Q3 25 | $106.0M | $416.1M | ||
| Q2 25 | $117.2M | $291.0M | ||
| Q1 25 | $112.0M | $314.5M | ||
| Q4 24 | $113.0M | $320.6M | ||
| Q3 24 | $129.0M | $298.4M | ||
| Q2 24 | $123.8M | $319.1M | ||
| Q1 24 | $142.9M | $201.2M |
总债务CLFDRYTM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | — | — |
股东权益CLFDRYTM
| Q4 25 | $249.7M | $139.1M | ||
| Q3 25 | $256.2M | $148.8M | ||
| Q2 25 | $264.5M | $-11.9M | ||
| Q1 25 | $265.9M | $18.9M | ||
| Q4 24 | $267.4M | $21.7M | ||
| Q3 24 | $275.8M | $11.2M | ||
| Q2 24 | $274.6M | $39.3M | ||
| Q1 24 | $279.2M | $61.6M |
总资产CLFDRYTM
| Q4 25 | $268.1M | $480.2M | ||
| Q3 25 | $306.2M | $506.9M | ||
| Q2 25 | $314.7M | $372.7M | ||
| Q1 25 | $310.9M | $386.7M | ||
| Q4 24 | $303.2M | $392.3M | ||
| Q3 24 | $315.3M | $363.6M | ||
| Q2 24 | $318.1M | $381.8M | ||
| Q1 24 | $315.4M | $258.7M |
负债/权益比CLFDRYTM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.4M | $-25.4M |
| 自由现金流经营现金流 - 资本支出 | $-2.4M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 2.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CLFDRYTM
| Q4 25 | $-1.4M | $-25.4M | ||
| Q3 25 | — | $-26.6M | ||
| Q2 25 | $7.9M | $-23.3M | ||
| Q1 25 | $3.0M | $-40.4M | ||
| Q4 24 | $7.2M | $-18.8M | ||
| Q3 24 | $22.2M | $-25.2M | ||
| Q2 24 | $4.0M | $-29.1M | ||
| Q1 24 | $-5.7M | $-40.7M |
自由现金流CLFDRYTM
| Q4 25 | $-2.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.5M | — | ||
| Q1 25 | $654.0K | — | ||
| Q4 24 | $5.1M | — | ||
| Q3 24 | $18.2M | — | ||
| Q2 24 | $2.8M | — | ||
| Q1 24 | $-7.7M | — |
自由现金流率CLFDRYTM
| Q4 25 | -7.1% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 15.1% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 17.1% | — | ||
| Q3 24 | 323.0% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | -20.8% | — |
资本支出强度CLFDRYTM
| Q4 25 | 2.9% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 71.4% | — | ||
| Q2 24 | 2.5% | — | ||
| Q1 24 | 5.3% | — |
现金转化率CLFDRYTM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
